A study reported that naïve CD4+ T-cells can predict CAR T therapy success in large B-cell lymphoma, addressing variability in real-world outcomes. The research aims to identify immune biomarkers tied to response, moving beyond trial averages to better forecast individual patient trajectories. CAR T remains highly effective for some patients, but response rates and durability vary—making patient selection and early stratification central to expanding access safely. By linking naïve helper T-cell status to response, the findings offer a candidate tool for risk assessment and mechanistic insight into how the immune environment shapes outcomes. The excerpt does not include effect sizes or threshold definitions, but the premise is directly relevant for translational biomarker development across CAR T platforms.